Cargando…
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib...
Autores principales: | Johnson, Douglas B., Menzies, Alexander M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088759/ https://www.ncbi.nlm.nih.gov/pubmed/37041273 http://dx.doi.org/10.1038/s41571-023-00762-1 |
Ejemplares similares
-
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016) -
Immunomodulation by the Panton-Valentine leukocidin can benefit the host during Staphylococcus aureus infections
por: Yoong, Pauline
Publicado: (2013) -
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012) -
Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
por: Tanabe, Junya, et al.
Publicado: (2020) -
Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)